预约演示
更新于：2026-10-21
Enavogliflozin
依那格列净
更新于：2026-10-21
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 韩国 (2022-12-06), |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H27ClO6 |
InChIKeyKORCWPOBTZTAFI-YVTYUBGGSA-N |
CAS号1415472-28-4 |
关联
47
项与 依那格列净 相关的临床试验NCT07619833
A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus
NCT07240844
Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy - A Randomized, Double-Blind, Placebo-Controlled, Crossover, Multicenter Trial
RBR-8ks2vwn
A phase I, single-center, double-blind, randomized, parallel, placebo-controlled clinical study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability after a single dose and multiple doses of 0.3 mg, 0.6 mg, and 1.2 mg Enavogliflozin in healthy adult participants of both sexes - SYN 374.002.24 / AC2025-PK/PD-105-1 - ENVLO - ENVLO ENaVoglifLOzin – Brazil
100 项与 依那格列净 相关的临床结果
登录后查看更多信息
100 项与 依那格列净 相关的转化医学
登录后查看更多信息
100 项与 依那格列净 相关的专利（医药）
登录后查看更多信息
37
项与 依那格列净 相关的文献（医药）2026-11-01NEUROPHARMACOLOGY
Enavogliflozin alleviates motor deficits in rotenone-induced Parkinson's disease mice via attenuation of oxidative stress and neuroinflammation as well as activation of the SIRT1/PINK1/Parkin pathway
Article
作者: Wang, Lixia ; Pang, Xiaoyan ; Sun, Siyu ; Liang, Tengfei ; Yan, Hexin ; Liu, Qiaoqiao
Parkinson's disease is an age-related neurodegenerative disorder characterized by the progressive degeneration of nigrostriatal dopaminergic neurons. Enavogliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor, has recently been demonstrated to exert neuroprotective effects. However, whether enavogliflozin can ameliorate motor behavioral deficits in Parkinson's disease currently remains unclear. To this end, this study aimed to investigate the neuroprotective effects of enavogliflozin on Parkinson's disease and explore its underlying molecular mechanisms. We established a Parkinson's disease model using rotenone-induced C57BL/6 mice (1.5 mg/kg/d, 3 weeks, i.p.) to investigate the neuropharmacological modulation effects of enavogliflozin treatment (0.1 and 1 mg/kg/d, 3 weeks, p.o., 2 h after rotenone injection) on Parkinson's disease from the perspectives of motor behavioral evaluation, pathological changes, oxidative stress, neuroinflammation, and SIRT1/PINK1/Parkin signaling pathways in specific brain regions. The results revealed that enavogliflozin alleviated neuropathological alterations of the substantia nigra, upregulated tyrosine hydroxylase and dopamine transporter expression in nigrostriatal dopaminergic neurons, and improved motor behavioral deficits. Administration of enavogliflozin further significantly reduced the levels of inflammatory cytokines (IL-6 and TNF-α), microglial activation, and oxidative damage in rotenone-induced Parkinson's disease mice. Moreover, we found that enavogliflozin activated PINK1/Parkin-mediated mitophagy by SIRT1 signaling pathway. In conclusion, enavogliflozin ameliorates motor dysfunction in rotenone-induced Parkinson's disease mice by attenuating oxidative stress, inhibiting neuroinflammation, and activating SIRT1/PINK1/Parkin pathway. These findings support a neuroprotective and preventive role for enavogliflozin in Parkinson's disease.
2026-09-01Diabetes & Metabolism Journal
Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs
Article
作者: Lee, Chang Beom ; Cho, Jae Min ; Kim, Sang-Yong ; Sattanon, Sarinya ; Heo, Jung A ; Sony, Kiran ; Kim, Younghee ; Min, Kyung Wan ; Hong, Jun Hwa ; Chamnan, Parinya ; Kim, Jae Hyeon ; Nah, Jae Jin ; Park, Mi Hee ; Sirirak, Thanitha ; Kim, Hae Jin
Background: The study evaluated the efficacy and safety of enavogliflozin, a novel, promising selective sodium-glucose cotransporter 2 inhibitor, as an add-on in adults with type 2 diabetes mellitus (T2DM) inadequately controlled with insulin alone or combined with other antidiabetic drugs (OADs).Methods: The double-blind, placebo-controlled, multicenter trial was conducted in South Korea and Thailand. Individuals with glycosylated hemoglobin (HbA1c) ≥7.5% after ≥8-week treatment with background insulin alone or combined with ≤2 OADs were randomized to receive enavogliflozin 0.3 mg or placebo (n=120 each) for 24 weeks. The primary outcome was a change in HbA1c at week 24. Secondary outcomes included, among others, changes in body weight, blood pressure, and other measures of glycemic control. Adverse events (AEs) were investigated throughout the study (Clinical trial registration number: NCT05466643).Results: At week 24, the placebo-adjusted mean change in HbA1c from baseline in the enavogliflozin group was –0.9% (P<0.001). Also, placebo-adjusted mean changes in fasting plasma glucose (–32.4 mg/dL, <i>P<0.001), body weight (–1.3 kg, <i>P<0.001), and total daily dose of insulin (–1.3 units, <i>P=0.010) at week 24 were statistically significant. In addition, a significant decrease in blood pressure and fasting C-peptide was observed in the enavogliflozin group, along with a significant increase in homeostasis model assessment of β-cell function, yet without a concomitant change in homeostasis model assessment of insulinresistance. No significant increase in treatment-related AEs was observed for enavogliflozin.Conclusion: Enavogliflozin 0.3 mg/day is an efficacious and safe add-on treatment option in T2DM patients controlled inadequately with insulin alone or combined with OADs.
2026-09-01DIABETES OBESITY & METABOLISM
Enavogliflozin Improves Non‐invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials
Letter
作者: Kim, Hae Jin ; Lee, Areum ; Kim, So Hun ; Chon, Suk ; Yu, Sung Hoon ; Jang, Min Kyoung ; Lee, Han Sol ; Jeong, In Kyung ; Lee, Yong‐Ho ; Jeoung, Su‐Jin ; Jung, Chang Hee
36
项与 依那格列净 相关的新闻（医药）2026-07-12
抗体药物偶联物临床3期临床结果申请上市临床申请
2026-03-05
100 项与 依那格列净 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D13015 | - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 韩国 | 2022-12-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病肾脏病 | 临床3期 | 韩国 | 2024-09-23 | |
| 射血分数保留型心力衰竭 | 临床3期 | 韩国 | 2023-10-25 | |
| 三尖瓣闭锁不全 | 临床3期 | 韩国 | 2023-10-25 | |
| 糖尿病性视网膜病变 | 临床申请批准 | 韩国 | 2023-09-14 | |
| 黄斑水肿 | 临床申请批准 | 韩国 | 2023-09-14 | |
| 糖尿病 | 临床前 | 韩国 | 2022-01-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 240 | 蓋遞壓願積齋製壓鹽蓋(獵醖範淵憲齋鬱簾窪壓): LSM Change = -0.92 (95.0% CI, -1.155 ~ -0.694), P-Value = <0.001 更多 | 积极 | 2025-09-15 | |||
Placebo | |||||||
临床3期 | 146 | 鑰衊選憲鹽蓋製顧範範(蓋蓋齋簾鏇獵衊構網衊) = The proportions of participants reaching HbA1c 7.0% (53 mmol/mol) at Week 52 were 69.4% in the maintenance group and 65.4% in the switch group. 鹽齋醖構廠繭範醖願網 (網衊鹹醖艱窪製選鬱觸 ) | 积极 | 2024-10-01 | |||
Placebo | |||||||
| - | 63 | 壓構鏇襯簾糧艱淵構糧(網齋遞選選觸廠糧獵簾) = 鹽艱製蓋壓繭淵淵蓋觸 範鬱膚夢簾衊襯憲餘憲 (淵繭窪鹽淵醖廠繭餘餘 ) 更多 | 积极 | 2024-07-01 | |||
安慰剂 | 壓構鏇襯簾糧艱淵構糧(網齋遞選選觸廠糧獵簾) = 鹹鬱製淵觸齋獵觸膚鬱 範鬱膚夢簾衊襯憲餘憲 (淵繭窪鹽淵醖廠繭餘餘 ) 更多 | ||||||
PRNewswire 人工标引  | 临床3期 | - | 壓選網獵簾築鹽壓簾顧(積襯獵簾簾簾顧遞淵糧) = 獵製膚觸膚觸鹹積廠糧 夢顧壓醖鹽願艱淵膚築 (壓獵鹽鑰鏇膚餘鏇製願 ) | 积极 | 2024-06-19 | ||
壓選網獵簾築鹽壓簾顧(積襯獵簾簾簾顧遞淵糧) = 憲鹽積簾選願繭選選鹹 夢顧壓醖鹽願艱淵膚築 (壓獵鹽鑰鏇膚餘鏇製願 ) | |||||||
临床3期 | 182 | 構鹹簾餘繭淵築選範鏇(夢簾選構齋廠窪鬱醖簾) = 簾觸糧廠糧廠願繭簾憲 窪齋簾顧鹹觸鹽繭餘艱 (窪糧構範廠蓋鏇艱襯繭 ) 更多 | 积极 | 2024-06-01 | |||
(Type 2 Diabetes Mellitus + Switch from dapagliflozin to enavogliflozin) | 構鹹簾餘繭淵築選範鏇(夢簾選構齋廠窪鬱醖簾) = 網淵構繭蓋壓夢鑰鏇糧 窪齋簾顧鹹觸鹽繭餘艱 (窪糧構範廠蓋鏇艱襯繭 ) 更多 | ||||||
临床3期 | 2型糖尿病 追加 | 200 | 鏇觸製艱鹽齋構鑰壓構(鏇鏇醖淵衊醖觸簾鹹醖) = 憲夢積餘蓋範膚鬱鏇壓 憲鏇襯構膚鹽鏇襯遞醖 (壓糧膚顧糧醖鏇選衊襯 ) 更多 | 积极 | 2023-02-09 | ||
鏇觸製艱鹽齋構鑰壓構(鏇鏇醖淵衊醖觸簾鹹醖) = 壓齋鬱淵淵構獵獵鏇膚 憲鏇襯構膚鹽鏇襯遞醖 (壓糧膚顧糧醖鏇選衊襯 ) 更多 | |||||||
临床3期 | 160 | 齋鏇襯壓夢繭築襯壓艱(繭構鬱構艱餘壓壓積遞): P-Value = <0.001 | 积极 | 2022-01-25 | |||
Placebo | |||||||
临床1期 | 糖尿 glucosuria | - | 觸餘壓簾網壓憲夢鏇醖(醖鑰餘鑰夢選蓋築膚壓) = DWP16001 was well tolerated in all dose groups, and all adverse events were mild in severity 製範糧觸窪膚鑰夢繭齋 (遞積憲築壓廠築鹽選夢 ) 更多 | 积极 | 2019-09-19 | ||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用